OBJECTIVE: Our purpose was to examine the efficacy of a topical long-term treatment with boric acid versus an oral long-term treatment (itraconazole) in the cure and prevention of recurrent vulvovaginal candidiasis. STUDY DESIGN: A prospective, nonrandomized study of patients affected by recurrent vulvovaginal candidiasis was undertaken. In 3 years we recruited 22 consecutive patients who underwent therapy with itraconazole (group 1) or boric acid (group 2). Women were followed up for 1 year, with clinic and microbiologic controls after 1, 3, 6, and 12 months after the first visit. RESULTS: During the treatment, the positive culture results (15.1% vs 12.1%) and the signs and symptoms (33.3% vs. 24.2%) were similar within the 2 groups, with no significant statistical difference. With the withdrawal, after 6 months relapses were common in the 2 groups (54.5%). CONCLUSIONS: Boric acid seems to be a valid and promising therapy both in the cure of the vaginal infection and in the prevention of relapses of recurrent vulvovaginal candidiasis, but its efficacy ends with the suspension of the therapy.
OBJECTIVE: Our purpose was to examine the efficacy of a topical long-term treatment with boric acid versus an oral long-term treatment (itraconazole) in the cure and prevention of recurrent vulvovaginal candidiasis. STUDY DESIGN: A prospective, nonrandomized study of patients affected by recurrent vulvovaginal candidiasis was undertaken. In 3 years we recruited 22 consecutive patients who underwent therapy with itraconazole (group 1) or boric acid (group 2). Women were followed up for 1 year, with clinic and microbiologic controls after 1, 3, 6, and 12 months after the first visit. RESULTS: During the treatment, the positive culture results (15.1% vs 12.1%) and the signs and symptoms (33.3% vs. 24.2%) were similar within the 2 groups, with no significant statistical difference. With the withdrawal, after 6 months relapses were common in the 2 groups (54.5%). CONCLUSIONS:Boric acid seems to be a valid and promising therapy both in the cure of the vaginal infection and in the prevention of relapses of recurrent vulvovaginal candidiasis, but its efficacy ends with the suspension of the therapy.
Authors: Claire S Danby; Dina Boikov; Rina Rautemaa-Richardson; Jack D Sobel Journal: Antimicrob Agents Chemother Date: 2012-01-09 Impact factor: 5.191
Authors: Anna Powell; Khalil G Ghanem; Linda Rogers; Ashley Zinalabedini; Rebecca M Brotman; Jonathan Zenilman; Susan Tuddenham Journal: Sex Transm Dis Date: 2019-12 Impact factor: 2.830
Authors: Dina A Boikov; Jeffrey B Locke; Kenneth D James; Ken Bartizal; Jack D Sobel Journal: J Antimicrob Chemother Date: 2017-05-01 Impact factor: 5.790
Authors: Kathryn W Woodburn; L Edward Clemens; Jesse Jaynes; Lydia-Marie Joubert; Alfred Botha; Hasan Nazik; David A Stevens Journal: Antimicrob Agents Chemother Date: 2019-10-22 Impact factor: 5.191
Authors: Gilbert Donders; István Oszkár Sziller; Jorma Paavonen; Phillip Hay; Francesco de Seta; Jean Marc Bohbot; Jan Kotarski; Jordi Antoni Vives; Bela Szabo; Ramona Cepuliené; Werner Mendling Journal: Front Cell Infect Microbiol Date: 2022-09-09 Impact factor: 6.073